Although I intend to shy away from the cult of celebrity, a recent clip from Tom Hanks resonated with me regarding the current state of the biotech market. As Mr Hanks continues his evolution into that trusted grandfatherly type of statesman, he spoke sagely with a group of peers and juniors reminding them all that “This too shall pass”.
By Robert Clarke, CEO of Kinaset, as part of the From The Trenches feature of LifeSciVC.
White Hat Hackers, sometimes called “ethical hackers,” are individuals that work to find and fix security problems in a system by exploiting its entry points. They don’t use their computers like the rest of us do. While most of us start our workdays by firing up a laptop, clicking a web browser icon and moving through a series of user-friendly, color-coded steps, white hat hackers spend their days looking at black screens strewn with code that seems unintelligible to the untrained eye. It’s as if they are getting behind the screen, peering deep inside the inner workings of the computer where they can unlock secret functions and reprogram conventional behaviors.
By Jonathan Montagu, CEO and founder of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC.
Imagine yourself setting out to do business in Japan. You step off the plane, check into your hotel, take a quick nap and then head to a restaurant to meet your potential new Japanese colleagues. You shake hands, sit down, enjoy a delicious meal, talk business – get straight to the deal – and then graciously pick up the check when it arrives at the table. It’s the beginning of a beautiful relationship.
By Deanna Petersen, CBO of AVROBIO, and Ted Tanaka, consultant with Tanaka International LLC, as part of the From The Trenches feature of LifeSciVC
Day One Biopharmaceuticals appears to be living up to its namesake of altering pediatric cancer care from day one, unveiling positive initial data for its brain tumor drug that saw its share price double on Monday morning.
2022 has brought unique challenges for growing companies. Capital markets, shifting regulatory winds and other emergent forces are driving tough decisions on programs, personnel, and strategy (see discussion on framing these decisions).
By Ankit Mahadevia, CEO of Spero Therapeutics, as part of the From The Trenches feature of LifeSciVC